| Product Code: ETC13149405 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Neuropathic Pain Market was valued at USD 7.5 Billion in 2024 and is expected to reach USD 10.5 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The Global Neuropathic Pain Market is experiencing steady growth due to the rising prevalence of neuropathic pain conditions such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. Factors contributing to market expansion include the increasing geriatric population, higher awareness about neuropathic pain management, and the development of novel treatment options. The market is characterized by a competitive landscape with key players focusing on research and development activities to introduce innovative therapies. The market is segmented based on drug class, including anticonvulsants, antidepressants, opioids, and topical treatments. Geographically, North America and Europe are significant markets due to advanced healthcare infrastructure and high adoption rates of advanced pain management therapies. However, emerging markets in Asia-Pacific and Latin America are expected to witness substantial growth opportunities in the coming years.
The Global Neuropathic Pain Market is experiencing significant growth driven by increasing prevalence of chronic pain conditions, advancements in drug development, and rising awareness about pain management. Key trends include the growing adoption of non-opioid medications, such as anticonvulsants and antidepressants, for neuropathic pain treatment, as well as the development of novel therapies targeting specific pain pathways. Opportunities in the market lie in the untapped potential of emerging markets, technological innovations like wearable pain relief devices, and the expansion of personalized medicine approaches for more targeted and effective treatments. Additionally, collaborations between pharmaceutical companies and research institutions are likely to drive further innovation and product development in the neuropathic pain market.
The Global Neuropathic Pain Market faces several challenges, including limited understanding of the underlying mechanisms of neuropathic pain, leading to difficulties in developing effective treatments. Another challenge is the variability in patient responses to available treatments, highlighting the need for personalized medicine approaches. Additionally, the high cost of neuropathic pain medications and limited insurance coverage in some regions pose barriers to access for patients. The lack of standardized diagnostic tools and the stigma associated with chronic pain also contribute to the challenges in effectively managing neuropathic pain. Overall, addressing these challenges requires continued research efforts, collaboration among healthcare professionals, and increased awareness to improve outcomes for patients suffering from neuropathic pain.
The global neuropathic pain market is primarily driven by factors such as the increasing prevalence of chronic pain conditions, rising geriatric population, advancements in pain management technologies, and growing awareness about the available treatment options. Additionally, the rising incidence of conditions such as diabetes, cancer, and multiple sclerosis, which are associated with neuropathic pain, further contribute to the market growth. Moreover, the development of novel therapeutics, such as gene therapy and targeted drug delivery systems, along with the expanding research and development activities in the field of neuropathic pain management, are expected to propel market expansion. Furthermore, the improving healthcare infrastructure in developing countries and the growing demand for effective pain management solutions are also key drivers shaping the global neuropathic pain market landscape.
Government policies related to the Global Neuropathic Pain Market vary across countries. In the United States, the FDA plays a crucial role in regulating the approval and marketing of neuropathic pain medications. The agency`s guidelines and requirements impact drug development, clinical trials, and market access for pharmaceutical companies. In Europe, the European Medicines Agency (EMA) also regulates the approval process for neuropathic pain treatments, ensuring safety and efficacy standards are met. Additionally, reimbursement policies and healthcare systems in different countries influence market dynamics, affecting patient access to innovative therapies. Overall, government policies play a significant role in shaping the landscape of the Global Neuropathic Pain Market, impacting research, development, approval, and commercialization of treatments for this debilitating condition.
The Global Neuropathic Pain Market is expected to witness significant growth in the coming years, driven by factors such as an increasing prevalence of neuropathic pain conditions, a growing geriatric population, and advancements in treatment options. The market is likely to expand with the development of novel therapeutics and innovative treatment approaches, including non-pharmacological interventions and targeted drug delivery systems. Additionally, the rising awareness about neuropathic pain and improving healthcare infrastructure in emerging economies are anticipated to contribute to market growth. However, challenges such as high treatment costs and limited access to healthcare services in certain regions may hinder the market`s progress. Overall, the Global Neuropathic Pain Market is poised for expansion, fueled by technological advancements and a growing focus on improving patient outcomes.
In the global neuropathic pain market, North America holds a significant share due to the high prevalence of chronic pain conditions and the availability of advanced healthcare infrastructure. Europe follows closely behind, driven by increasing awareness about neuropathic pain and a growing geriatric population. In Asia, the market is poised for rapid growth, attributed to the rising healthcare expenditure, improving healthcare facilities, and a large patient pool. The Middle East and Africa region is also witnessing growth, primarily due to the increasing prevalence of diabetes and other chronic diseases leading to neuropathic pain. Latin America is expected to show steady growth, supported by improving healthcare access and rising investments in healthcare infrastructure. Overall, these regional insights reflect a promising outlook for the global neuropathic pain market with diverse growth opportunities across different geographies.
Global Neuropathic Pain Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Neuropathic Pain Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Neuropathic Pain Market Revenues & Volume, 2021 & 2031F |
3.3 Global Neuropathic Pain Market - Industry Life Cycle |
3.4 Global Neuropathic Pain Market - Porter's Five Forces |
3.5 Global Neuropathic Pain Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Neuropathic Pain Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Global Neuropathic Pain Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.8 Global Neuropathic Pain Market Revenues & Volume Share, By Procedure, 2021 & 2031F |
3.9 Global Neuropathic Pain Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.10 Global Neuropathic Pain Market Revenues & Volume Share, By Modality, 2021 & 2031F |
3.11 Global Neuropathic Pain Market Revenues & Volume Share, By Mode of Purchase, 2021 & 2031F |
3.12 Global Neuropathic Pain Market Revenues & Volume Share, By Pain Type, 2021 & 2031F |
3.13 Global Neuropathic Pain Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Global Neuropathic Pain Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Neuropathic Pain Market Trends |
6 Global Neuropathic Pain Market, 2021 - 2031 |
6.1 Global Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Neuropathic Pain Market, Revenues & Volume, By Spinal Cord Stimulation (SCS) Devices, 2021 - 2031 |
6.1.3 Global Neuropathic Pain Market, Revenues & Volume, By External Peripheral Nerve Stimulation, 2021 - 2031 |
6.1.4 Global Neuropathic Pain Market, Revenues & Volume, By Transcutaneous Electrical Nerve Stimulation (Tens) Devices, 2021 - 2031 |
6.2 Global Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Neuropathic Pain Market, Revenues & Volume, By Rechargeable and Non-Rechargeable, 2021 - 2031 |
6.3 Global Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Neuropathic Pain Market, Revenues & Volume, By Invasive and Non-Invasive, 2021 - 2031 |
6.4 Global Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Neuropathic Pain Market, Revenues & Volume, By Transcutaneous Electrical Nerve Stimulation, 2021 - 2031 |
6.4.3 Global Neuropathic Pain Market, Revenues & Volume, By Transcranial Magnetic Stimulation, 2021 - 2031 |
6.4.4 Global Neuropathic Pain Market, Revenues & Volume, By Respiratory Electrical Stimulation, 2021 - 2031 |
6.5 Global Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Neuropathic Pain Market, Revenues & Volume, By Stationary, 2021 - 2031 |
6.5.3 Global Neuropathic Pain Market, Revenues & Volume, By Portable, 2021 - 2031 |
6.6 Global Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
6.6.1 Overview & Analysis |
6.6.2 Global Neuropathic Pain Market, Revenues & Volume, By Over-the-Counter Devices, 2021 - 2031 |
6.6.3 Global Neuropathic Pain Market, Revenues & Volume, By Prescription-Based Devices, 2021 - 2031 |
6.7 Global Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
6.7.1 Overview & Analysis |
6.7.2 Global Neuropathic Pain Market, Revenues & Volume, By Peripheral Neuropathy, 2021 - 2031 |
6.7.3 Global Neuropathic Pain Market, Revenues & Volume, By Entrapment Neuropathy, 2021 - 2031 |
6.7.4 Global Neuropathic Pain Market, Revenues & Volume, By Phantom Limb Neuropathy, 2021 - 2031 |
6.7.5 Global Neuropathic Pain Market, Revenues & Volume, By Trigeminal Neuralgia, 2021 - 2031 |
6.7.6 Global Neuropathic Pain Market, Revenues & Volume, By Post Herpetic Neuralgia (PHN), 2021 - 2031 |
6.7.7 Global Neuropathic Pain Market, Revenues & Volume, By Post Traumatic Neuropathy, 2021 - 2031 |
6.7.8 Global Neuropathic Pain Market, Revenues & Volume, By Foot Pain, 2021 - 2031 |
6.7.9 Global Neuropathic Pain Market, Revenues & Volume, By Coccydynia, 2021 - 2031 |
6.8 Global Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.8.1 Overview & Analysis |
6.8.2 Global Neuropathic Pain Market, Revenues & Volume, By Spinal Stenosis, 2021 - 2031 |
6.8.3 Global Neuropathic Pain Market, Revenues & Volume, By Chemotherapy-Induced Peripheral Neuropathy, 2021 - 2031 |
6.8.4 Global Neuropathic Pain Market, Revenues & Volume, By Diabetic Neuropathy, 2021 - 2031 |
6.8.5 Global Neuropathic Pain Market, Revenues & Volume, By Others, 2021 - 2031 |
7 North America Neuropathic Pain Market, Overview & Analysis |
7.1 North America Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
7.2 North America Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.5 North America Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
7.6 North America Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.7 North America Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
7.8 North America Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
7.9 North America Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
7.10 North America Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
8 Latin America (LATAM) Neuropathic Pain Market, Overview & Analysis |
8.1 Latin America (LATAM) Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
8.4 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.5 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
8.6 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
8.7 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
8.8 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
8.9 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
8.10 Latin America (LATAM) Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
9 Asia Neuropathic Pain Market, Overview & Analysis |
9.1 Asia Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
9.4 Asia Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.5 Asia Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
9.6 Asia Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
9.7 Asia Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
9.8 Asia Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
9.9 Asia Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
9.10 Asia Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
10 Africa Neuropathic Pain Market, Overview & Analysis |
10.1 Africa Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
10.4 Africa Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.5 Africa Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
10.6 Africa Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
10.7 Africa Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
10.8 Africa Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
10.9 Africa Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
10.10 Africa Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
11 Europe Neuropathic Pain Market, Overview & Analysis |
11.1 Europe Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
11.4 Europe Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.5 Europe Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
11.6 Europe Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
11.7 Europe Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
11.8 Europe Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
11.9 Europe Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
11.10 Europe Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
12 Middle East Neuropathic Pain Market, Overview & Analysis |
12.1 Middle East Neuropathic Pain Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Neuropathic Pain Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Neuropathic Pain Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Neuropathic Pain Market, Revenues & Volume, By Type, 2021 - 2031 |
12.4 Middle East Neuropathic Pain Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.5 Middle East Neuropathic Pain Market, Revenues & Volume, By Procedure, 2021 - 2031 |
12.6 Middle East Neuropathic Pain Market, Revenues & Volume, By Technology, 2021 - 2031 |
12.7 Middle East Neuropathic Pain Market, Revenues & Volume, By Modality, 2021 - 2031 |
12.8 Middle East Neuropathic Pain Market, Revenues & Volume, By Mode of Purchase, 2021 - 2031 |
12.9 Middle East Neuropathic Pain Market, Revenues & Volume, By Pain Type, 2021 - 2031 |
12.10 Middle East Neuropathic Pain Market, Revenues & Volume, By Indication, 2021 - 2031 |
13 Global Neuropathic Pain Market Key Performance Indicators |
14 Global Neuropathic Pain Market - Export/Import By Countries Assessment |
15 Global Neuropathic Pain Market - Opportunity Assessment |
15.1 Global Neuropathic Pain Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Neuropathic Pain Market Opportunity Assessment, By Type, 2021 & 2031F |
15.3 Global Neuropathic Pain Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.4 Global Neuropathic Pain Market Opportunity Assessment, By Procedure, 2021 & 2031F |
15.5 Global Neuropathic Pain Market Opportunity Assessment, By Technology, 2021 & 2031F |
15.6 Global Neuropathic Pain Market Opportunity Assessment, By Modality, 2021 & 2031F |
15.7 Global Neuropathic Pain Market Opportunity Assessment, By Mode of Purchase, 2021 & 2031F |
15.8 Global Neuropathic Pain Market Opportunity Assessment, By Pain Type, 2021 & 2031F |
15.9 Global Neuropathic Pain Market Opportunity Assessment, By Indication, 2021 & 2031F |
16 Global Neuropathic Pain Market - Competitive Landscape |
16.1 Global Neuropathic Pain Market Revenue Share, By Companies, 2024 |
16.2 Global Neuropathic Pain Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |